Alexander Drilon, MD
Thoracic Oncologist & Early Drug Development Specialist
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Chief, Early Drug Development Service
I am a medical oncologist who specializes in the treatment of lung cancer. I work with a team of experts including surgeons, radiation oncologists, pathologists, and nurses. Our goal is to provide the best possible care and support for patients and their families.
Read more
As a member of the Thoracic Oncology Service, my research is focused on developing new treatments for lung cancer. I have a particular interest in studying ways to target molecular changes in patients’ tumors with new medicines.
I also specialize in early-phase clinical trials and am a member of our Developmental Therapeutics group. Our aim is to bring new drugs to patients with all types of cancer, particularly those for whom standard treatments have been exhausted.
I speak English, Spanish, and Filipino.
My Specialties
- Lung Cancer
- Early-Phase Clinical Trials
Education
- MD, University of the Philippines
Residencies
- Internal Medicine - St. Luke's-Roosevelt Hospital Center
Fellowships
- Medical Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine; Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Drilon sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Drilon
- A Phase 1/2 Study of BBI-355 in People With Advanced Solid Tumors
- A Phase I Study of LOXO-260 in People with Solid Tumors Containing RET Gene Changes
- A Phase I Study of NVL-520 in People with Solid Tumors
- A Phase I Study of NVL-655 in People with Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Read more
- A Phase I Study of PF-07284892 in People with Advanced Solid Tumors
- A Phase I Study of TAS0953/HM06 in People with RET-Mutated Advanced Solid Tumors
- A Phase I/II Study of REGN5093-M114 in People with Advanced Non-Small Cell Lung Cancer
- A Phase I/II Study of TPX-0005 in Patients with Advanced Solid Tumors
- A Phase II Study of Cabozantinib in Patients with Advanced Non-Small Cell Lung Cancer
- A Phase III Study of Selpercatinib after Surgery or Radiation Therapy for RET Fusion-Positive Lung Cancer
- Clinical Trials Co-Investigated by Dr. Drilon
- A Phase 1 Study of KIN-2787 in People With Advanced Cancers
- A Phase 1/2 Study of MRTX1133 in People With Solid Tumors That Have a KRAS G12D Gene Mutation
- A Phase I Study of ELU001 in People Who Have Solid Tumors Associated with High Levels of FR-Alpha
- A Phase I Study of ERAS-601 Alone or with a MEK inhibitor for People with Advanced or Metastatic Solid Tumors
- A Phase I Study of Sapanisertib and Telaglenastat in Patients with Advanced Non-Small Cell Lung Cancer
- A Phase I/II Study of MCLA-128 in People with Advanced Solid Tumors with NRG1 Gene Fusions
- A Phase II Study of Milademetan in People with Advanced Solid Tumors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Drilon’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alexander Drilon discloses the following relationships and financial interests:
-
AbbVie
Provision of Services -
American Society of Clinical Oncology (ASCO)
Provision of Services -
Amgen
Provision of Services -
Answers in CME (AiCME)
Provision of Services -
Associazione Italiana Oncologia Toracica (AIOT)
Provision of Services -
Axis Medical Education
Provision of Services -
Bayer
Provision of Services -
Chugai Pharmaceuticals
Provision of Services -
Clinical Care Options
Provision of Services -
Creative Educational Concepts, Inc.
Provision of Services -
EPG Communication Holdings Ltd
Provision of Services -
Elevation Oncology, Inc.
Provision of Services -
Entos, Inc.
Provision of Services -
Harborside Press LLC
Provision of Services -
Helsinn Healthcare SA
Provision of Services -
Hospital Sirio-Libanes
Provision of Services -
Imedex, Inc.
Provision of Services -
Janssen Scientific Affairs, LLC
Provision of Services -
Liberum Independent Medical Education
Provision of Services -
Lilly Oncology
Provision of Services -
Loxo Oncology
Provision of Services -
Lung Cancer Canada
Provision of Services (uncompensated) -
Lung Cancer Research Foundation
Provision of Services (uncompensated) -
MBrace Therapeutics, Inc.
Ownership / Equity Interests
-
MJH Life Sciences
Provision of Services -
MORE Health, Inc
Provision of Services -
Med Learning Group
Provision of Services -
Medscape
Provision of Services -
Monte Rosa Therapeutics, Inc.
Provision of Services -
Novartis Pharmaceuticals Corporation
Provision of Services -
Nuvalent, Inc.
Provision of Services -
Ology Medical Education
Provision of Services -
OncLive
Provision of Services -
OncologyEducation
Provision of Services -
Oregon Health & Science University School of Medicine
Provision of Services -
PeerView Institute for Medical Education (PVI)
Provision of Services -
Pfizer, Inc.
Provision of Services -
Physicians' Education Resource
Provision of Services -
Prelude Therapeutics
Provision of Services -
RV Mais Eventos
Provision of Services -
Research to Practice
Provision of Services -
Thomas Jefferson University
Provision of Services -
Touch Independent Medical Education Ltd
Provision of Services -
Treeline Biosciences, Inc.
Ownership / Equity Interests; Provision of Services -
Universidad Autónoma de Madrid
Provision of Services -
Vindico Medical Education
Provision of Services -
i3 Health
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].